Nama's AI scorecard currently rates Guardant Health Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does GH report earnings?

Guardant Health's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.28.

What is the GH price target?

The median analyst price target from 25 analysts is $203.00, with a range of $105.00 – $240.00.

Is GH Shariah compliant?

Nama's AAOIFI-style screen reads Guardant Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Guardant Health (GH)

Healthcare · Diagnostics Research · NASDAQ

Guardant Health (GH) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $20.25B and a free-cash-flow yield of -1.2%. Over the most recent reported fiscal year, revenue grew 32.9%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +74.9% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-21.0%

How far the last close sits under the highest price of the past five years.

Market cap	$20.25B
Trailing P/E	—
Price / book	—
Price / sales	17.1
FCF yield	-1.2%
Dividend yield	—
Gross margin	65.0%
Operating margin	-39.8%
Net margin	-38.3%
Revenue growth (YoY)	+32.9%
Revenue growth (3-yr annual)	+29.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

GH earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.28). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.29	-$0.31	+6.5%	—
Q2 2026	Jul 30, 2026	-$0.42	-$0.39	-7.7%	$334.98M
Q1 2026	May 7, 2026	-$0.45	-$0.47	+4.3%	$301.67M
Q4 2025	Feb 19, 2026	-$0.50	-$0.47	-6.4%	$281.27M

GH analyst price target

Median target $203.00 from 25 analysts, ranging $105.00 – $240.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live GH data on Nama Insights →

Recent Congressional trades

Guardant Health trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Jonathan Jackson	House	Buy	$15,001 - $50,000	Oct 19, 2026

GH FAQ

Is GH a buy?: Nama's AI scorecard currently rates Guardant Health Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does GH report earnings?: Guardant Health's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.28.
What is the GH price target?: The median analyst price target from 25 analysts is $203.00, with a range of $105.00 – $240.00.
Is GH Shariah compliant?: Nama's AAOIFI-style screen reads Guardant Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.